Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis
Immunoglobulin light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by production and deposition of misfolded immunoglobulin light chains into target tissues, leading to end-organ damage. Most therapeutic interventions are adapted from experience in multiple myeloma (MM) and directed at eradicating the pathologic plasma cells that produce circulating amyloidogenic free light chains. However, unlike in MM, in AL amyloidosis therapeutic choice is limited by the enhanced susceptibility to toxicity of organs affected by amyloid deposition.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Heather Landau, Oscar Lahoud, Sean Devlin, Nikoletta Lendvai, David J. Chung, Ahmet Dogan, C. Ola Landgren, Sergio Giralt, Hani Hassoun Tags: Brief Article Source Type: research
More News: Amyloidosis | Biology | Dexamethasone | Hematology | Myeloma | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants | Velcade